Oncology Biosimilars Market 2026 with the Current State of the
Industry, Major Provincial Sectors, key players such as Amgen Inc.,
Allergan, Plc, Mylan N.V., Samsung Bioepis Co., Ltd., Teva
Pharmaceutical Industries Ltd., Pfizer Inc.
Biosimilar is a biological product that resembles a reference product and is not difference from
the already approved reference product. These are relatively cheaper than branded or approved
products. Several biologics for oncology have already lost their patents, and some are in its
period of expiry. As more products are expected to lose patents, biosimilar is expected to gain
popularity. Leading generic players such as Mylan N.V., Teva Pharmaceutical Industries Ltd,
Allergan Plc, Sandoz (a Novartis International AG’s division) are expected to capitalize on these
patent expiries and may establish themselves as dominating players in oncology biosimilars
market.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1305
Rapid approval of biosimilars for oncology is expected to be a major driving factor for growth
of the oncology biosimilars market over the forecast period
There was about a decade gap in approval of first biosimilars in two key markets, Europe and
the U.S. First biosimilar was approved in 2006 in Europe, however, in the U.S. first product
was approved in 2015. But since approving the first biosimilar, the FDA has approved five
products in 2017. Out of these five biosimilars, two were approved for oncology. First,
oncology biosimilar Mvasi (bevacizumab-awwb) received approval in September 2017, and
second one, Ogivri (trastuzumab) was approved in December 2017. In Europe, both of the
products have been approved, and Mvasi received approval from European Commission in
January 2018.